Advances in Structure–Activity Relationship Studies on Potassium Channel Modulators - Ion Channels and Their Inhibitors - page 264

63. Saini L, Gupta SP, Satuluri VSAK (2009) A QSAR study on some series of sodium and
potassium channel blockers. Med Chem 5:570-576
64. Yuan P, Leonetti MD, Pico AR et al (2010) Structure of the human BK channel Ca 2+ -
activation apparatus at 3.0 A resolution". Science 329:182-186
65. Calderone V (2002) Large-conductance, Ca +2 -activated K + channels: function, pharmacology
and drugs. Curr Med Chem 9:1385-1395
66. Wu S-N (2003) Large-conductance Ca 2+ -activated K + channels: physiological role and

pharmacology. Curr Med Chem 10:649-661
67. Coi A, Fiamingo FL, Livi O et al (2009) QSAR studies on BK channel activators. Bioorg Med
Chem 17:319-325
68. Zunkler BJ (2006) Human ether-a-go-go-related (HERG) gene and ATP-sensitive potassium
channels as targets for adverse drug effects. Pharmacol Ther 112:12-37
69. Wang Q, Bowles NE, Towbin JA (1998) The molecular basis of long QT syndrome and
prospects for therapy. Mol Med Today 4:382-388
70. Rajamani R, Tounge BA, Li J et al (2005) A two-state homology model of the hERG K +
channel: application to ligand binding. Bioorg Med Chem Lett 15:1737-1741
71. Song M, Clark M (2006) Development and evaluation of an in silico model for hERG binding.
J Chem Inf Model 46:392-400
72. Aronov AM (2006) Common pharmacophores for uncharged human ether-a-go-go-related
gene (hERG) blockers. J Med Chem 49:6917-6921
73. Sanchez-Capula JA, Salinas-Stefanon E, Torres-Jacome J et al (2001) Blockade of currents by
the antimalarial drug chloroquine in feline ventricular myocytes. J Pharmacol Exp Ther
297:437-445
74. Ficker E, Obejero-Paz CA, Zhao S et al (2002) The binding site for channel blockers that
rescue misprocessed human long QT syndrome type 2 ether-a-go-go-related gene (HERG)
mutations. J Biol Chem 277:4989-4998
75. Borosy AP, Keseru K, Penzes I et al (2000) 3D QSAR study of class I antiarrhythmics. J Mol
Struct THEOCHEM 503:113-129
76. Matyus P, Borosy AP, Varro A et al (1998) Development of pharmacophores for inhibitors of
the rapid component of the cardiac delayed rectifier potassium current. Int J Quantum Chem
69:21-30
77. Ekins S, Crumb WJ, Sarazan RD et al (2002) Three-dimensional quantitative structure-
activity relationship for inhibition of human ether-a-go-go-related gene potassium channel.
J Pharmacol Exp Ther 301:427-434
78. Cavalli A, Poluzzi E, De Ponti F et al (2002) Toward a pharmacophore for drugs inducing the
long QT syndrome: insights from a CoMFA study of HERG K + channel blockers. J Med
Chem 45:3844-3853
79. Rampe D, Murawsky MK, Grau J et al (1998) The antipsychotic agent sertindole is a high
affinity antagonist of the human cardiac potassium channel HERG. J Pharmacol Exp Ther
286:788-793
80. Pearlstein RA, Vaz RJ, Kang J et al (2003) Characterization of HERG potassium channel
inhibition using CoMSiA 3D QSAR and homology modeling approaches. Bioorg Med Chem
Lett 13:1829-1835
81. SYBYL 6.7.2 Tripos Inc., 1699 S. Hanley Rd., St. Louis, MO 631444 USA
82. Garg D, Gandhi T, Mohan CG (2008) Exploring QSTR and toxicophore of Herg K + channel
blockers using GFA and HypoGen techniques. J Mol Graph Model 26:966-976
83. Catalyst, Version 4.10 A. (2005). San Diego, Inc., CA, USA